Whitehawk Therapeutics (WHWK) AI Stock Analysis

• Market Cap: $106.51M
• Dividend Yield: N/A
• Average Volume (3M): 3.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.52
• Revenue Growth: -42.62%
• EPS Growth: N/A
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 47,128,360
• 10 Day Avg. Volume: 9,835,549
• 30 Day Avg. Volume: 3,352,856
• PEG Ratio: 0.41
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 3.29
• P/FCF Ratio: -1.40
• Enterprise Value/Market Cap: -0.45
• Enterprise Value/Revenue: -2.22
• Enterprise Value/Gross Profit: 9.41
• Enterprise Value/Ebitda: 0.50
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $2.50 ▲(8.70% Upside)

The overall stock score for Whitehawk Therapeutics is primarily impacted by its financial performance challenges, including persistent losses and negative cash flows. Technical analysis shows a positive price trend, but momentum is weak. The valuation is reasonable, but the lack of a dividend yield may limit appeal. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Strategic Partnerships

The collaboration with Tempus AI enhances Whitehawk's research capabilities and supports its oncology pipeline, potentially leading to innovative therapies and expanded market reach.

Balance Sheet Health

A strong equity position with minimal leverage provides financial stability, allowing Whitehawk to invest in R&D and weather financial challenges without excessive debt burden.

Revenue Growth

Consistent revenue growth indicates expanding market reach and product adoption, which is crucial for long-term sustainability and competitiveness in the biotech industry.

Negative Factors

Profitability Challenges

Ongoing profitability challenges suggest the need for strategic adjustments to improve cost management and operational efficiency, impacting long-term financial health.

Cash Flow Issues

Negative cash flow indicates insufficient cash generation from operations, which can limit the company's ability to fund R&D and strategic initiatives without external financing.

Operational Losses

Sustained operational losses highlight the need for improved efficiency and cost control to achieve profitability and ensure long-term viability in the competitive biotech sector.

Whitehawk Therapeutics Business Overview & Revenue Model

Company Description

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

How the Company Makes Money

Whitehawk Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which often involve licensing agreements for its proprietary drug candidates. The company may also earn income from research and development grants, as well as potential milestone payments tied to the achievement of specific development and regulatory goals. Additionally, if successful, Whitehawk Therapeutics could benefit from royalties on sales of its therapies once they are commercialized, contributing to its overall revenue stream.

Whitehawk Therapeutics Financial Statement Overview

Summary

Whitehawk Therapeutics is facing significant financial challenges, with persistent losses and negative cash flows. While the company has shown some revenue growth, its profitability metrics are concerning, and it needs to address its cost structure and operational efficiency. The balance sheet is relatively strong with low leverage, but the lack of profitability and cash flow generation are critical areas that require attention to ensure long-term sustainability and growth.

Income Statement

Whitehawk Therapeutics has shown a consistent increase in revenue over the years, with a revenue growth rate of 6.7% from 2023 to 2024. However, the company is struggling with negative gross profit margins and net profit margins, indicating that costs are significantly outweighing revenue. The EBIT and EBITDA margins are also negative, reflecting ongoing operational losses. These factors suggest financial instability and a need for strategic adjustments to improve profitability.

Balance Sheet

The company's balance sheet shows a strong equity position with a high equity ratio of 74.6% in 2024, indicating financial stability in terms of asset financing. However, the debt-to-equity ratio is low at 0.02, suggesting minimal leverage, which can be a double-edged sword in terms of growth potential. The return on equity is negative due to ongoing net losses, highlighting the challenge of generating returns for shareholders.

Cash Flow

Whitehawk Therapeutics is experiencing negative free cash flow, although there was a slight improvement from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. The free cash flow to net income ratio is also negative, underscoring the company's cash flow challenges and the need for improved cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.60M	25.98M	24.35M	15.22M	1.12M	14.58M
Gross Profit	-5.10M	-28.07M	-27.38M	-18.78M	-18.55M	-428.00K
EBITDA	-96.72M	-64.63M	-71.76M	-58.80M	-36.96M	-2.54M
Net Income	-10.42M	-63.69M	-65.77M	-60.51M	-110.09M	-3.48M
Balance Sheet
Total Assets	180.82M	70.32M	132.42M	184.24M	157.91M	18.82M
Cash, Cash Equivalents and Short-Term Investments	177.20M	47.24M	108.84M	172.56M	148.99M	4.46M
Total Debt	0.00	833.00K	1.27M	1.66M	605.00K	10.26M
Total Liabilities	8.76M	17.84M	27.23M	25.86M	21.50M	31.26M
Stockholders Equity	172.07M	52.48M	105.19M	158.38M	136.41M	-12.43M
Cash Flow
Free Cash Flow	-96.49M	-61.20M	-63.63M	-50.08M	-22.47M	-12.70M
Operating Cash Flow	-95.56M	-59.55M	-59.66M	-49.64M	-22.42M	-12.70M
Investing Cash Flow	104.89M	25.20M	83.21M	-132.89M	25.15M	0.00
Financing Cash Flow	94.40M	130.00K	326.00K	72.62M	141.80M	1.19M

Whitehawk Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.18, above the 50-day MA of 2.15, and above the 200-day MA of 1.95, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.22 is Neutral, neither overbought nor oversold. The STOCH value of 80.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WHWK.

Whitehawk Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WHWK	56 Neutral	$106.51M	-31.52	-13.82%	―	-42.62%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADVM	49 Neutral	$91.84M	-0.49	-417.79%	―	-100.00%	-42.12%
ORMP	47 Neutral	$113.44M	2.84	24.38%	―	―	814.20%
MGNX	45 Neutral	$93.62M	―	-81.13%	―	-9.70%	23.23%
CNTX	37 Underperform	$103.82M	―	-33.68%	―	―	69.30%
SPRB	35 Underperform	$111.83M	-1.22	-167.93%	―	-90.18%	-17.93%

Whitehawk Therapeutics Corporate Events

Whitehawk Therapeutics Reports Q3 2025 Financial Results

Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on developing advanced antibody drug conjugate (ADC) cancer treatments by leveraging established tumor biology and innovative technologies. The company aims to address difficult-to-treat cancers with its engineered ADC portfolio.

Whitehawk Therapeutics Advances ADC Portfolio Amid Financial Growth

Whitehawk Therapeutics, Inc. is an oncology therapeutics company focused on developing advanced ADC cancer treatments by leveraging established tumor biology. The company operates within the biotechnology sector and is known for its innovative approach to addressing difficult-to-treat cancers.